AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) has announced the opening of its new centers in Philadelphia and Boston, bringing the total to 21 locations across the U.S. The company specializes in premium body contouring procedures utilizing its proprietary AirSculpt technology, known for its minimally invasive approach that facilitates faster healing and more precise results. Over 30,000 procedures have been conducted nationally, indicating a robust demand for their services. The Boston center opened in July, while the Philadelphia center is centrally located near King of Prussia Mall.
AirSculpt Technologies (NASDAQ: AIRS) has announced that it will release its third quarter results on November 10, 2022, after market close. Following this, a conference call will be held on November 11, 2022, at 8:30 AM ET for investors and the public to discuss the results. Access to the call is available via phone or through a webcast on the company's investor relations website. AirSculpt is known for its proprietary AirSculpt® method, which offers a minimally invasive body contouring procedure aiming to deliver significant results for patients.
AirSculpt Technologies (NASDAQ: AIRS) announced management's participation at the Piper Sandler Growth Frontiers Conference in Nashville, TN on September 13, 2022. The event will include 1x1 investor meetings and a fireside chat at 5:00 PM ET. A live webcast and replay will be accessible on AirSculpt's investor relations site.
AirSculpt specializes in premium body contouring procedures, using its proprietary AirSculpt® method for minimally invasive fat removal, aiming to deliver exceptional results for patients.
AirSculpt Technologies (NASDAQ: AIRS) has introduced AirSculpt Smooth, a new cellulite removal procedure that is FDA-cleared and minimally invasive. This one-time procedure offers complete removal of stubborn cellulite dimples and is designed to be performed alongside AirSculpt's fat removal method. Clients can expect to resume normal activities within 24-48 hours. The procedure utilizes the Aveli device from Revelle Aesthetics and aims to provide lasting results that improve over three months, enhancing the body contouring experience.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) reported a strong second quarter for 2022, with a 42% year-over-year revenue increase to $49.7 million. The company declared a $0.41 per share special cash dividend, payable on September 14, 2022. Despite revenue growth, net income fell to $0.6 million, impacted by rising equity-based compensation and public company costs. Year-to-date results show a 46% revenue increase to $89.2 million. The company maintains a revenue outlook of $175-$179 million for 2022 and aims to open four new centers annually.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) announced a special cash dividend of $0.41 per share to be paid on September 14, 2022, for shareholders on record as of August 26, 2022. This decision reflects the Board of Directors' confidence in the company's long-term growth potential and strong financial position, as stated by Chairman Adam Feinstein. The dividend will be funded by excess cash from operations, while ensuring continued financial flexibility for future business growth.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) announced the release of its second quarter results, scheduled for August 12, 2022, before market open. Following the results, a conference call will occur at 8:30 a.m. Eastern Time, accessible by phone or a webcast on the company's investor relations page. AirSculpt is known for its premium body contouring procedures using the proprietary AirSculpt® method, which offers minimally invasive fat removal. The company continues to focus on delivering the best results for its patients.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) reported a robust first quarter for 2022, with cases increasing by 31.1% to 3,156, and revenue soaring by 51.3% to $39.5 million. The company noted significant growth in same-center metrics, with cases up 12.2% and revenue per case up 14.6%. However, a net loss of $(0.7) million was reported, compared to a net income of $6.6 million last year. Adjusted EBITDA slightly increased to $9.8 million. The company has raised its full-year revenue outlook to between $175-$179 million.
AirSculpt Technologies (NASDAQ: AIRS) will announce its first quarter results on May 13, 2022, before the market opens. A conference call will follow at 8:30 a.m. Eastern Time, accessible via phone or webcast. Investors can participate by calling 1-877-407-9716 for US calls, or 1-201-493-6779 for international calls. A replay will be available shortly after the call. AirSculpt specializes in body contouring procedures under the Elite Body Sculpture brand, utilizing their proprietary AirSculpt® method for effective fat removal.
AirSculpt Technologies (NASDAQ:AIRS) reported strong financial results for Q4 and full year 2021. Q4 case volume grew by 43.8% to 2,885, with revenue increasing 64.4% to $37.6 million. For the full year, cases rose 87.8% to 11,050 and revenue jumped 112.4% to $133.3 million. Notably, adjusted EBITDA reached $46.1 million, marking a 163.5% increase. However, the company recorded a net loss of $14.2 million in Q4 compared to a net income of $5.6 million last year. For 2022, revenue is projected to rise by 29% to 32%. The company maintains a solid liquidity position with $25.3 million in cash.